Absci (NASDAQ:ABSI) Posts Earnings Results, Misses Estimates By $0.02 EPS

Absci (NASDAQ:ABSI) announced its earnings results on Tuesday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02), FiscalAI reports. Absci had a negative return on equity of 66.32% and a negative net margin of 6,450.76%.The company had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.92 million.

Here are the key takeaways from Absci’s conference call:

• ABS-201 interim Phase 1 results were encouraging: Management reported favorable safety and tolerability, with an estimated half-life of at least 65 days and modeling suggesting two to three doses could maintain more than 90% prolactin-receptor occupancy over six months.
• Multiple upcoming clinical catalysts remain on schedule. The company expects interim 13-week proof-of-concept data for pattern hair loss later in 2026, full 26-week data in early 2027, and plans to initiate a Phase 2 endometriosis study in the fourth quarter of 2026.
• Eli Lilly partnership and new financing strengthen resources. Lilly invested $40 million and is collaborating on ABS-201’s clinical development, while Absci’s June financing generated approximately $93.6 million in net proceeds and extended projected funding into the second half of 2028.
• Absci is expanding its AI drug-discovery platform with Atlas, which integrates literature, genetics, and single-cell data to identify targets before feeding them into the Origin molecule-design platform; management said the technology has already suggested additional prolactin-related indications.
• The company remains dependent on unproven clinical and commercial assumptions: durability of hair regrowth will not be established by the 13- or 26-week readouts, and the cited market opportunities and product profile are based partly on modeling, consumer research, and hypothetical profiles rather than clinical efficacy results.

Absci Stock Up 1.0%

NASDAQ:ABSI opened at $9.50 on Thursday. The business has a 50 day moving average price of $8.75 and a two-hundred day moving average price of $5.43. The company has a market cap of $1.48 billion, a P/E ratio of -11.45 and a beta of 2.35. Absci has a twelve month low of $2.24 and a twelve month high of $12.06.

Institutional Investors Weigh In On Absci

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. ARK Investment Management LLC grew its holdings in shares of Absci by 3.2% in the 4th quarter. ARK Investment Management LLC now owns 12,550,799 shares of the company’s stock valued at $43,802,000 after acquiring an additional 388,026 shares in the last quarter. Vanguard Group Inc. lifted its stake in Absci by 12.9% in the third quarter. Vanguard Group Inc. now owns 7,281,918 shares of the company’s stock valued at $22,137,000 after acquiring an additional 830,336 shares during the last quarter. State Street Corp increased its position in Absci by 190.1% during the fourth quarter. State Street Corp now owns 5,990,877 shares of the company’s stock worth $20,908,000 after buying an additional 3,925,926 shares during the last quarter. Geode Capital Management LLC raised its stake in Absci by 6.1% in the 4th quarter. Geode Capital Management LLC now owns 3,239,623 shares of the company’s stock valued at $11,309,000 after acquiring an additional 186,708 shares during the period. Finally, Ameriprise Financial Inc. boosted its holdings in shares of Absci by 24.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 3,191,011 shares of the company’s stock worth $9,701,000 after buying an additional 625,451 shares during the period. 52.05% of the stock is owned by institutional investors.

Key Stories Impacting Absci

Here are the key news stories impacting Absci this week:

• Positive Sentiment: Absci announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201, supporting the potential of its generative-AI drug-discovery platform. The company also secured a $100 million underwritten financing, including a $40 million strategic investment from Eli Lilly, and said its cash, cash equivalents and marketable securities should fund operations into the second half of 2028. Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: Needham & Company reaffirmed its “Buy” rating and set an $11 price target, implying roughly 16% upside from $9.50. Benzinga analyst coverage
• Positive Sentiment: BTIG Research also reaffirmed a “Buy” rating and assigned a $13 price target, implying approximately 37% upside from $9.50. Benzinga analyst coverage
• Neutral Sentiment: The $100 million financing strengthens Absci’s liquidity but may create dilution for existing shareholders. The Lilly investment is strategically supportive, while the offering’s equity issuance could limit some of the benefit.
• Negative Sentiment: Second-quarter results missed expectations: Absci reported a loss of $0.21 per share versus the $0.19 consensus estimate and revenue of $0.32 million versus expectations of $0.89 million. The company remains unprofitable, with a negative return on equity and net margin. Absci second-quarter results
• Neutral Sentiment: Reported short-interest data showed zero shares and zero days to cover, suggesting no measurable short-position pressure; however, the figures appear unreliable and provide little actionable insight.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. Truist Financial raised their target price on shares of Absci from $11.00 to $17.00 and gave the company a “buy” rating in a research note on Thursday, July 2nd. BTIG Research restated a “buy” rating and set a $13.00 target price on shares of Absci in a report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Absci in a research note on Friday, July 17th. Guggenheim upped their price objective on shares of Absci from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, June 15th. Finally, Leerink Partners assumed coverage on Absci in a report on Thursday, June 4th. They set an “outperform” rating and a $12.00 target price on the stock. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Absci has an average rating of “Moderate Buy” and an average price target of $13.43.

About Absci

Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications.

The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework.